Equities Analysts Issue Forecasts for ABCL FY2024 Earnings

AbCellera Biologics Inc. (NASDAQ:ABCL) – Stock analysts at Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for AbCellera Biologics in a research report issued on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.59) per share for the year, down from their previous forecast of ($0.56). The consensus estimate for AbCellera Biologics’ current full-year earnings is ($0.55) per share. Leerink Partnrs also issued estimates for AbCellera Biologics’ Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.63) EPS.

AbCellera Biologics (NASDAQ:ABCL) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). AbCellera Biologics had a negative return on equity of 15.54% and a negative net margin of 533.32%. The business had revenue of $6.51 million for the quarter, compared to the consensus estimate of $8.95 million. During the same quarter in the prior year, the company earned ($0.10) earnings per share.

A number of other equities analysts have also recently issued reports on the stock. Benchmark reiterated a “hold” rating on shares of AbCellera Biologics in a research report on Tuesday. KeyCorp reiterated an “overweight” rating and issued a $5.00 price target (down from $7.00) on shares of AbCellera Biologics in a research note on Thursday, July 11th. Finally, Stifel Nicolaus restated a “buy” rating and set a $12.00 price objective (down previously from $14.00) on shares of AbCellera Biologics in a research report on Tuesday.

AbCellera Biologics Price Performance

ABCL stock opened at $2.72 on Thursday. The firm has a 50-day moving average price of $2.63 and a 200-day moving average price of $3.05. AbCellera Biologics has a 12 month low of $2.34 and a 12 month high of $6.05.

Institutional Investors Weigh In On AbCellera Biologics

Institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of AbCellera Biologics in the 1st quarter valued at about $454,000. State Board of Administration of Florida Retirement System acquired a new stake in AbCellera Biologics during the 1st quarter valued at approximately $239,000. Nan Fung Group Holdings Ltd raised its holdings in AbCellera Biologics by 307.1% during the 1st quarter. Nan Fung Group Holdings Ltd now owns 50,971 shares of the company’s stock worth $231,000 after purchasing an additional 38,450 shares during the last quarter. Baker BROS. Advisors LP lifted its position in shares of AbCellera Biologics by 20.1% in the 1st quarter. Baker BROS. Advisors LP now owns 27,525,640 shares of the company’s stock worth $124,691,000 after purchasing an additional 4,615,887 shares during the period. Finally, Intellectus Partners LLC boosted its stake in shares of AbCellera Biologics by 0.7% in the 2nd quarter. Intellectus Partners LLC now owns 545,533 shares of the company’s stock valued at $1,615,000 after purchasing an additional 3,750 shares during the last quarter. 61.42% of the stock is owned by institutional investors.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.